Decisions, Decisions: Selecting Among the Increasing Array of Treatments and Combinations for Patients With Advanced BRAF-Positive Melanoma

1.00 CME
60 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

hemonc

Overview

Provider Statement

This continuing medical education activity is provided by: National Jewish Health

Educational Partner: Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.


Activity Description

Advances in BRAF-targeted agents and their integration into treatment algorithms for patients diagnosed with BRAF-mutated melanoma have dramatically enhanced clinical outcomes. However, for patients diagnosed with advanced disease, challenges exist for identifying those who will benefit from first-line targeted therapy versus immune-based therapies. Recent data on triple therapy combining dual BRAF and MEK inhibition (BRAFi/MEKi) with anti-programmed cell death (anti-PD1) checkpoint blockade in the first-line setting for advanced disease has added yet another option for consideration. The optimal sequencing of regimens for treating advanced BRAF-mutated melanoma remains a very active area of investigation. As data become available on new combination and sequencing approaches, as well as treatment-associated toxicity, ongoing education is needed to guide clinicians in the selection of appropriate therapy based on patient and disease characteristics. In this educational activity, experts present emerging data on targeted agents, checkpoint inhibitors, and combinations for patients with BRAF-mutated melanoma. They will review patient, disease, and/or treatment characteristics that may inform clinical decision-making on initial therapy for advanced disease. And finally, faculty will discuss emerging combination approaches, including sequencing and toxicity considerations, for patients with advanced BRAF-positive melanoma. This expert panel discussion features an interactive learning platform and case discussions to provide insight on how new developments in the treatment of BRAF-mutated melanoma may impact clinical care. 


Target Audience

The intended audience for this activity is hematologist-oncologists, oncologists and other health care professionals involved in the management of patients with advanced BRAF-positive melanoma.


Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Assess the latest evidence regarding the use of targeted agents, checkpoint inhibitors, and combinations for patients with BRAF-mutated melanoma.
  • Describe patient, disease, and/or treatment characteristics that may inform first-line clinical decision making for patients with BRAF-mutated melanoma and apply to practice accordingly.
  • Review emerging combination approaches, including sequencing and toxicity considerations, for patients with advanced BRAF-positive melanoma and how these approaches may impact clinical care.

Activity Chair

Steven J. O’Day, MD
Executive Director
John Wayne Cancer Institute and Cancer Clinic
Regional Director of Clinical Research
Professor of Medical Oncology
Saint John's Health Center
Santa Monica, CA


Faculty

Georgina V. Long, BSc, PhD, MBBS, FRACP
Professor of Melanoma Medical Oncology and Translational Research
Co-Medical Director
Melanoma Institute Australia
The University of Sydney
North Sydney, NSW, Australia

John M. Kirkwood, MD
Usher Professor of Medicine, Dermatology, and Translational Science
University of Pittsburgh Cancer Institute
Director, Melanoma and Skin Cancer Center
UPMC Hillman Cancer Center
Pittsburgh, PA


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP 
Anthony Gerber, MD, PhD


Accreditation

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 15, 2020, to December 14, 2021.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, you will be issued an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty reports the following relationship(s)

Steven J. O’Day, MD
Consulting Fee: Agenus, Biothera, Bristol-Myers Squibb, Exicure, Immunosync, Merck
Speakers Bureau: Bristol-Myers Squibb
Contracted Research: Agenus, Biothera, Bristol-Myers Squibb, Exicure, Genocea, ImaginAb, Merck, Shattuck Labs, Vyriad

John M. Kirkwood, MD
Consulting Fee: Amgen, Bristol-Myers Squibb, Checkmate, Novartis
Contracted Research: Amgen, Bristol-Myers Squibb, Castle Biosciences, Checkmate, Immunocore, Iovance, Novartis

Georgina V. Long, BSc, PhD, MBBS, FRACP
Consulting Fee: Aduro Biotech, Amgen, Array Biopharma, Boehringer Ingelheim, Bristol-Myers Squibb, Highlight Therapeutics, Merck, Novartis, QBiotics, Regeneron, SkylineDx

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.  

Anthony Gerber, MD, PhD
Consultant: Appelis Pharmaceuticals, BeiGene, BioScience Pharma, Pliant Therapeutics

National Jewish Health and Vindico Medical Education staff report the following relationship(s)

Meghan Brenner, MA
No relevant financial relationships to disclose

Mandy Comeau 
No relevant financial relationships to disclose

Andrea Harshman, MHA, CHCP, CMP-HC
No relevant financial relationships to disclose

Lynn Hayne
No relevant financial relationships to disclose

Lynda Lyons
No relevant financial relationships to disclose

Jillian Scavone, PhD
No relevant financial relationships to disclose

Signed disclosures are on file at National Jewish Health and Vindico Medical Education.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices. 


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of National Jewish Health and Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of National Jewish Health and Vindico Medical Education. Neither National Jewish Health, Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com